CL2012003729A1 - Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion. - Google Patents
Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion.Info
- Publication number
- CL2012003729A1 CL2012003729A1 CL2012003729A CL2012003729A CL2012003729A1 CL 2012003729 A1 CL2012003729 A1 CL 2012003729A1 CL 2012003729 A CL2012003729 A CL 2012003729A CL 2012003729 A CL2012003729 A CL 2012003729A CL 2012003729 A1 CL2012003729 A1 CL 2012003729A1
- Authority
- CL
- Chile
- Prior art keywords
- benzimidazol
- quinolin
- piperazin
- disintegrant
- fluoro
- Prior art date
Links
- QDPVYZNVVQQULH-UHFFFAOYSA-N 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one 2-hydroxypropanoic acid hydrate Chemical compound O.CC(O)C(O)=O.C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 QDPVYZNVVQQULH-UHFFFAOYSA-N 0.000 title abstract 2
- 239000007884 disintegrant Substances 0.000 title abstract 2
- 239000000945 filler Substances 0.000 title abstract 2
- 239000000314 lubricant Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008203 oral pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composición farmacéutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o más rellenos, un desintegrante y un lubricante; proceso de preparación de la composición.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10168028 | 2010-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012003729A1 true CL2012003729A1 (es) | 2013-04-12 |
Family
ID=42751565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012003729A CL2012003729A1 (es) | 2010-06-30 | 2012-12-28 | Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion. |
Country Status (37)
Country | Link |
---|---|
US (1) | US9545402B2 (es) |
EP (2) | EP2588086B1 (es) |
JP (1) | JP6043281B2 (es) |
KR (2) | KR101840182B1 (es) |
CN (2) | CN106943355B (es) |
AR (1) | AR081776A1 (es) |
AU (1) | AU2011273519B2 (es) |
BR (1) | BR112012033479A8 (es) |
CA (1) | CA2801826C (es) |
CL (1) | CL2012003729A1 (es) |
CO (1) | CO6650354A2 (es) |
CR (1) | CR20120623A (es) |
CU (1) | CU20120177A7 (es) |
DK (1) | DK2588086T3 (es) |
DO (1) | DOP2012000324A (es) |
EA (1) | EA026244B1 (es) |
EC (1) | ECSP13012411A (es) |
ES (1) | ES2701161T3 (es) |
GE (1) | GEP20146049B (es) |
GT (1) | GT201200348A (es) |
HU (1) | HUE042355T2 (es) |
IL (1) | IL223799A (es) |
MA (1) | MA34387B1 (es) |
MX (1) | MX345404B (es) |
MY (2) | MY163369A (es) |
NI (1) | NI201200189A (es) |
NZ (1) | NZ604055A (es) |
PE (1) | PE20130481A1 (es) |
PL (1) | PL2588086T3 (es) |
PT (1) | PT2588086T (es) |
SG (1) | SG186182A1 (es) |
TN (1) | TN2012000574A1 (es) |
TR (1) | TR201818761T4 (es) |
TW (1) | TWI583384B (es) |
UA (1) | UA109659C2 (es) |
UY (1) | UY33472A (es) |
WO (1) | WO2012001074A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
US20140378422A1 (en) | 2012-01-31 | 2014-12-25 | Novartis Ag | Combination of a RTK inhibitor with an anti-estrogen and use thereof for the treatment of cancer |
US20150202203A1 (en) | 2012-07-11 | 2015-07-23 | Novartis Ag | Method of Treating Gastrointestinal Stromal Tumors |
US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
EP3482771B1 (en) | 2013-03-14 | 2023-01-18 | Société des Produits Nestlé S.A. | Manufacture of peanut formulations for oral desensitization |
US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
EP3570093B1 (en) | 2013-11-15 | 2021-09-15 | Tangible Science, Inc. | Contact lens with a hydrophilic layer |
WO2015187736A1 (en) * | 2014-06-02 | 2015-12-10 | Allergen Research Corporation | Placebo formulations and uses thereof |
AU2015360637B2 (en) | 2014-12-09 | 2019-08-22 | Tangible Science, Inc. | Medical device coating with a biocompatible layer |
TWI829098B (zh) | 2015-01-02 | 2024-01-11 | 美商梅拉洛伊卡公司 | 細菌組成物 |
CA2986522A1 (en) * | 2015-05-22 | 2016-12-01 | Novartis Ag | Pharmaceutical compositions |
KR20200083526A (ko) | 2017-11-02 | 2020-07-08 | 에이뮨 테라퓨틱스, 인코퍼레이티드 | 경구 면역요법 방법 |
US11229673B2 (en) | 2019-05-10 | 2022-01-25 | Société des Produits Nestlé S.A. | Methods for improving the quality of life of a patient with a peanut allergy |
US10835531B1 (en) | 2019-06-18 | 2020-11-17 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
US20230302139A1 (en) * | 2020-07-31 | 2023-09-28 | University Of Florida Research Foundation, Incorporated | Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5009897A (en) * | 1988-06-24 | 1991-04-23 | Abbott Laboratories | Pharmaceutical granules and tablets made therefrom |
BRPI0113757B1 (pt) | 2000-09-11 | 2017-05-23 | Chiron Corp | derivados de quinolinona como inibibores de tirosina quinase |
EP2573079A3 (en) | 2002-08-23 | 2015-03-11 | Novartis AG | Benzimidazole quinolinones and uses thereof |
US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
GB0504203D0 (en) * | 2005-03-01 | 2005-04-06 | Novartis Ag | Organic compounds |
SG154451A1 (en) * | 2005-05-23 | 2009-08-28 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
WO2007014124A2 (en) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
AU2006320591B2 (en) | 2005-11-29 | 2010-06-03 | Novartis Ag | Formulations of quinolinones |
CN101316593B (zh) * | 2005-11-29 | 2012-05-02 | 诺瓦提斯公司 | 喹啉酮类的制剂 |
CL2008000681A1 (es) | 2007-03-09 | 2008-10-24 | Novartis Ag | Metodo de tratamiento de melanoma mediante el uso de compuestos derivados de 4-amino-5-fluoro-(benzoimidazol sustituido)-1h-quinolin-2-ona. |
JP5645667B2 (ja) | 2007-11-08 | 2014-12-24 | アムビト ビオスシエンセス コルポラチオン | 増殖性疾患を治療するための、N−(5−tert−ブチル−イソキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,l−b][l,3]ベンゾチアゾール−2−イル]フェニル}尿素の投与方法 |
AR070924A1 (es) * | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
EP2108365A1 (en) * | 2008-04-09 | 2009-10-14 | LEK Pharmaceuticals d.d. | Single dosage pharmaceutical formulation comprising eprosartan mesylate |
MA34106B1 (fr) | 2010-04-16 | 2013-03-05 | Novartis Ag | Combinaison de composés organiques |
-
2011
- 2011-06-28 UY UY0001033472A patent/UY33472A/es not_active Application Discontinuation
- 2011-06-28 AR ARP110102271A patent/AR081776A1/es unknown
- 2011-06-29 HU HUE11734043A patent/HUE042355T2/hu unknown
- 2011-06-29 MX MX2012015091A patent/MX345404B/es active IP Right Grant
- 2011-06-29 DK DK11734043.0T patent/DK2588086T3/en active
- 2011-06-29 MA MA35575A patent/MA34387B1/fr unknown
- 2011-06-29 MY MYPI2012005339A patent/MY163369A/en unknown
- 2011-06-29 BR BR112012033479A patent/BR112012033479A8/pt not_active Application Discontinuation
- 2011-06-29 PE PE2012002517A patent/PE20130481A1/es not_active Application Discontinuation
- 2011-06-29 CN CN201710208616.1A patent/CN106943355B/zh active Active
- 2011-06-29 UA UAA201213966A patent/UA109659C2/uk unknown
- 2011-06-29 EA EA201291410A patent/EA026244B1/ru not_active IP Right Cessation
- 2011-06-29 AU AU2011273519A patent/AU2011273519B2/en active Active
- 2011-06-29 GE GEAP201112986A patent/GEP20146049B/en unknown
- 2011-06-29 EP EP11734043.0A patent/EP2588086B1/en active Active
- 2011-06-29 PT PT11734043T patent/PT2588086T/pt unknown
- 2011-06-29 PL PL11734043T patent/PL2588086T3/pl unknown
- 2011-06-29 WO PCT/EP2011/060949 patent/WO2012001074A2/en active Application Filing
- 2011-06-29 NZ NZ604055A patent/NZ604055A/en not_active IP Right Cessation
- 2011-06-29 CA CA2801826A patent/CA2801826C/en active Active
- 2011-06-29 JP JP2013517282A patent/JP6043281B2/ja active Active
- 2011-06-29 KR KR1020177035178A patent/KR101840182B1/ko active IP Right Grant
- 2011-06-29 KR KR1020137002390A patent/KR20130091319A/ko not_active Application Discontinuation
- 2011-06-29 EP EP18193864.8A patent/EP3446686A1/en active Pending
- 2011-06-29 SG SG2012089413A patent/SG186182A1/en unknown
- 2011-06-29 TR TR2018/18761T patent/TR201818761T4/tr unknown
- 2011-06-29 ES ES11734043T patent/ES2701161T3/es active Active
- 2011-06-29 US US13/703,120 patent/US9545402B2/en active Active
- 2011-06-29 CN CN2011800320095A patent/CN103068373A/zh active Pending
- 2011-06-29 TW TW100122927A patent/TWI583384B/zh not_active IP Right Cessation
- 2011-11-29 MY MYPI2016002052A patent/MY177741A/en unknown
-
2012
- 2012-12-05 TN TNP2012000574A patent/TN2012000574A1/en unknown
- 2012-12-11 CR CR20120623A patent/CR20120623A/es unknown
- 2012-12-20 NI NI201200189A patent/NI201200189A/es unknown
- 2012-12-20 IL IL223799A patent/IL223799A/en active IP Right Grant
- 2012-12-21 GT GT201200348A patent/GT201200348A/es unknown
- 2012-12-21 DO DO2012000324A patent/DOP2012000324A/es unknown
- 2012-12-24 CU CU2012000177A patent/CU20120177A7/es unknown
- 2012-12-27 CO CO12234898A patent/CO6650354A2/es not_active Application Discontinuation
- 2012-12-28 CL CL2012003729A patent/CL2012003729A1/es unknown
-
2013
- 2013-01-30 EC ECSP13012411 patent/ECSP13012411A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012003729A1 (es) | Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion. | |
AR114143A2 (es) | Formulaciones de comprimidos revestidos | |
HRP20190164T1 (hr) | Paraziticidni oralni veterinarski sastavi koji obuhvaćaju djelatne tvari sa sustavnim djelovanjem, i načini njihove primjene | |
NL300871I2 (nl) | ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat | |
MX2012003555A (es) | Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma. | |
TW201711676A (en) | Ferric citrate dosage forms | |
SV2010003744A (es) | Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina | |
BR112014025041B8 (pt) | Composição farmacêutica | |
EA201201202A1 (ru) | Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана | |
UY34166A (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
GEP201606595B (en) | (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) –nifuratel | |
EA201200485A1 (ru) | Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол | |
TN2012000477A1 (en) | Combination of organic compounds | |
DOP2015000089A (es) | Composición de difenidol de liberación prolongada | |
CY1118277T1 (el) | Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης | |
MX2015007945A (es) | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. | |
UY34081A (es) | Composición farmacéutica que comprende drotaverina | |
CL2009000790S1 (es) | Desodorizador de aire. | |
RS54402B1 (en) | NIFURATEL SULPHOXIDE FOR USE IN BACTERIAL INFECTION THERAPY | |
MX2012014498A (es) | Composicion farmaceutica de rosuvastatina. | |
TH1501001478A (th) | องค์ประกอบทางเภสัชกรรมสำหรับการให้ทางปากซึ่งมีการละลาย และ/หรือ การดูดซึมดีขึ้น | |
UY34865A (es) | Una composición acuosa que comprende dicamba y un agente de control de la deriva | |
TR200900104U (tr) | Çocuk muayene masası. | |
UY4219Q (es) | Articulo absorbente sanitario | |
UY4220Q (es) | Articulo absorbente sanitario |